DDInter1137 DDInter167
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis in women.
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Medrysone
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Hydrocortamate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
Medroxyprogesterone acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) USP22
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Palpitations
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Medroxyprogesterone acetate (Compound) resembles Hydrocortamate (Compound)
Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene)
Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease)
Medroxyprogesterone acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Medroxyprogesterone acetate (Compound) downregulates USP22 (Gene)
Medroxyprogesterone acetate (Compound) causes Palpitations (Side Effect)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Delavirdine